EGFR and neoplasm: Anti-CD3 x anti-EGFR bispecific antibody-armed activated T-cells (AATC) attach and selectively cross-link EGFR-expressing tumor cells and CD3-expressing T-cells, resulting in cytotoxic T-lymphocytes (CTLs) activation and selective cytotoxicity towards the EGFR-expressing tumor cells [80].